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Abstract 
Background 
Tick-borne encephalitis (TBE) is a central nervous system infection transmitted to humans by 
ticks. The causative agent, tick-borne encephalitis virus (TBEV), belongs to the genus 
Flavivirus (family Flaviviridae), which includes globally important arthropod-borne viruses, 
such as dengue, Yellow fever, Japanese encephalitis and West Nile viruses. Flaviviruses are 
highly cross-reactive in serological tests that are currently based on viral envelope proteins. 
The envelope (E) protein is the major antigenic determinant and it is known to induce 
neutralizing antibody responses. 
Methods 
We synthesized the full-length TBEV proteome as overlapping synthetic 18-mer peptides to 
find dominant linear IgG epitopes. To distinguish natural TBEV infections from responses to 
TBE immunization or other flavivirus infections, the peptides were probed with sera of 
patients infected with TBEV, West Nile virus (WNV) or dengue virus (DENV), sera from 
TBE vaccinees and negative control sera by SPOT array technique. 
Results 
We identified novel linear TBEV IgG epitopes in the E protein and in the nonstructural 
protein 5 (NS5). 
Conclusions 
In this study, we screened TBEV structural and nonstructural proteins to find linear epitopes 
specific for TBEV. We found 11 such epitopes and characterized specifically two of them to 
be potential for differential diagnostics. This is the first report of identifying dominant linear 
human B-cell epitopes of the whole TBEV genome. The identified peptide epitopes have 
potential as antigens for diagnosing TBEV and to serologically distinguish flavivirus 
infections from each other. 
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Introduction 
Tick-borne encephalitis virus (TBEV) is one of the most important neurotropic arthropod-
borne pathogens in Europe, causing nearly 3000 hospitalizations annually [1]. TBEV is 
endemic in many European countries, Russia and China. It is mainly transmitted by Ixodes 
ticks, but can also be transmitted via consumption of unpasteurized goat milk [2,3]. There are 
three subtypes of TBEV circulating in geographically distinct areas; namely European, 
Siberian, and Far Eastern. The variation at amino acid level is up to 5.6% between subtypes 
and 2.2% within a subtype [4]. 
The flavivirus virion is approximately 50 nm in diameter and displays icosahedral symmetry. 
The virion consists of three structural proteins (capsid C, prM and envelope E), the RNA 
genome, and a lipid membrane derived from the host cell. The flavivirus genome is a single-
stranded positive-sense RNA (approximately 11 kilobases), which is encapsidated by the C 
protein. The genome contains a single open reading frame, which encodes a polyprotein that 
is co- and post-translationally cleaved into ten proteins by viral and host proteases. The 
envelope protein E is a class II viral fusion protein. It consists of three distinct domains (I, II 
and III), and forms homodimers in a head to tail manner. In the virion, the homodimers 
further arrange into trimers parallel to each other. The other envelope protein, prM, is cleaved 
by furin during viral maturation and the pr moiety is released as a result of conformational 
changes. The seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) 
are found in the infected cell. NS1 is the only nonstructural protein that is glycosylated and 
secreted outside the cell. NS3 and NS2B form the viral serine protease that is required for 
post-translational modification of the polyprotein [5]. NS5 is a multifunctional protein 
containing an N-terminal methyl transferase domain and a C-terminal RNA-dependent RNA 
polymerase domain [6,7]. The other small nonstructural proteins (NS2A, NS4A and NS4B) 
are expected to function at least in the genome replication [8]. 
To date, the E and NS1 proteins are known to raise protective antibodies in infected humans, 
monkeys and mice [9]. PrM, does not elicit protective antibodies, but is probably required for 
the preservation of conformational epitopes of the E protein [10]. Previous studies suggest 
that infections with dengue (DENV), Japanese encephalitis (JEV) and West Nile (WNV) 
viruses can be differentiated by the antibody response to the prM protein [10,11]. For DENV 
type 1, some of the dominant epitopes in E and NS1 proteins have been identified using 
protein fragmentation methods [9]. In addition, AnandaRao et al. characterized several 
immunodominat linear B-cell epitopes in C and NS4A proteins of DENV using multi-pin 
peptide synthesis strategy [12]. 
In the present study, we used a peptide-based approach to identify immunodominat linear B-
cell epitopes from the entire TBEV genome, which have not been previously reported. We 
found TBEV-specific peptides in the E and NS5 proteins. The characterized epitopes showed 
potential in differentiating between other flavivirus infections, and between natural and 
vaccine-derived immunity to TBEV. 
Results 
Proteome-wide epitope screening 
A total of 567 overlapping linear 18-mer peptides were initially probed with pools of TBEV-
seronegative, acute TBEV-seropositive sera, and a pool of sera from TBEV-immunized 
individuals. Several epitope regions were identified in both structural and nonstructural parts 
of the TBEV proteome as highlighted by squares (peptides positive with either TBEV 
seropositive or TBEV-immunized pool) and circles (peptides positive only by TBEV-
immunized pool) in Figure 1A. We used densitometry to quantify the signal intensities of the 
peptides given by each pool, and plotted the signal intensity on a graph in parallel with Kyte 
and Doolittle hydrophilicity plots (Figure 1B). This quite expectedly showed that the 
antigenic regions overlapped with the hydrophilic regions throughout the proteome. To study 
which of the epitopes are dominant in TBEV-seropositive individuals, we probed the 
membrane next with individual serum samples of the TBEV seropositive serum pool. 
Peptides that were positive in at least 4/5 of the acute-phase samples, but remained negative 
in densitometric quantification with seronegative pool, were selected for further analysis 
(highlighted by squares in Figure 1A). In total, we identified 11 such IgG epitopes throughout 
the TBEV proteome (Table 1). 
Figure 1 SPOT array of TBEV proteome as overlapping peptides and prediction of 
antigenic regions A) SPOT array of TBEV coding region, acute TBEV-seropositive pool 
spots in rectangle, TBEV-immunized spots in circles, i) acute TBE-seropositive serum pool, 
ii) TBEV-seronegative serum pool and iii) TBEV-vaccinated serum pool. B) Kyte and 
Doolittle hydrophilicity plot of the TBEV genome corresponds to the signal intensities from 
the TBE seropositive and –negative serum pools. The window in Kyte and Doolittle 
hydrophilicity plot is 18. Amino acids in X-axis, signal intensities of the SPOT array in Y 
(TBEV-seropositive in blue, TBEV-seronegative in red), hydrophilicity (above) and 
hydrophobicity (below) in the upper X-axis. 
Table 1 Proteome-wide TBEV-specific linear epitope mapping 
Protein Index Virus Peptide sequence Sensitivity Vaccinated 
E 56 TBEV E N P A K T R E Y C L H A K L S D T 4/5 + 
E 74 TBEV G R K T A S F T V S S E K T I L T M 4/5 - 
E 85 TBEV L P W K H E G A Q N W N N A E R L V 5/5 + 
NS1 154 TBEV E C P L E R R K T G V F T V A E F G 4/5 - 
NS2B 244 TBEV A G L A A S A I H W S G I L G V M G 4/5 + 
NS3 340 TBEV P W L A W H V A A N V S S V T D R S 4/5 - 
NS4B 382 TBEV S E W T N V D I Q P A R S W G T Y V 4/5 - 
NS5 521 TBEV A L N T L T N I K V Q L I R M M E G 4/5 + 
NS5 531 TBEV P L D D R F G K A L Y F L N D M A K 4/5 - 
NS5 532 TBEV G K A L Y F L N D M A K T R K D I G 4/5 - 
NS5 552 TBEV W S I H A S G A W M T T E D M L D V 5/5 - 
Epitope characterization 
To further fine-map the identified eleven peptide epitopes, a new set of overlapping 18-mer 
peptides with a single amino acid shift were synthesized from a region including six 
additional amino acids in both N- and C-termini of the parent peptide, resulting in a total of 
13 peptides per each originally selected peptide. To evaluate the potential cross-reactivity 
between flaviviruses, we included the region corresponding to the parent peptide from 
heterologous flaviviruses (Table 2). The novel array was probed individually with a new 
panel of paired sera from six TBE-patients and 20 TBEV-seronegative sera (Table 3). With 
these samples, three of the original 11 peptides remained positive, two in E (E-74/38 and E-
85/59) and one in NS5 (NS5-521/198), when using a limit of at least 4/6 TBE-patients 
positive (in either acute or convalescent sample) and no more than 2/20 of TBEV-
seronegative samples positive (Table 4). Additionally, we probed the peptides with DENV-
seropositive (serotypes 1–4) and WNV-seropositive (four pools, four sera in each) sera. None 
of the three positive peptides reacted with DENV or WNV seropositive sera, which reacted 
with some of the DENV and WNV peptides, respectively. 
Table 2 Virus strains used for heterologous peptide synthesis 
Virus Strain GeneBank accession number 
TBEV European GU183380 
DENV1 Singapore S275/90 M87512 
DENV2 New Guinea C AF038403 
DENV3 strain H87 M93130 
DENV4 - AY94753 
LGTV - NC_003690 
OHFV - NC_005062 
LIV - NC_001809 
WNV Rabensburg isolate 97-103 AY765264 
WNV isolate WN NY 2000-crow3356 AF404756 
JEV - NC_001437 
USUV - NC_006551 
MVEV - NC_000943 
YFV 17D vaccine NC_002031 
Table 3 Paired TBEV-seropositive serum samples 
Sample Sample ID IgG IgM NT E-74/38 E-85/59 NS2B- 244/124 NS5- 521/197 NS5- 521/198 NS5- 521/206 
Acute GG15-44 + + <5 - + + - - + 
Convalescent GG15-339 + - 40 + + + + + + 
Acute GG5-36 + + <5 + + - - + - 
Convalescent GG5-198 + - 40 - + - + + - 
Acute GG12-62 + + 5 + + + + + + 
Convalescent GG12-286 + - 160 + + + - + + 
Acute GG38-126 + + <5 + + + + + + 
Convalescent GG38-128 + + 5 - + + - - - 
Acute GG33-102 + + <5 - - - - - - 
Convalescent GG33-344 + - 20 - - + - - - 
Acute GG57-194 + + <5 - + - - + + 
Convalescent GG57-590 + - 40 - + + + + + 
NT: neutralization titer. TBEV peptides in bold. 
Table 4 Specificity of the selected peptide epitopes 
Protein Index Virus Peptide sequence TBEV Neg. 
controls 
Vaccinated WNV 
pools 
DENV (1, 2, 
3 or 4) 
Overall 
sensitivity 
E 56/7 TBEV E N P A K T R E Y C L H A K L S D T 3/6 2/20 3/8 2/4 2/4 7/11 
E 74/38 TBEV A S F T V S S E K T I L T M G E Y G 4/6 2/20 1/8 0/4 0/4 8/11 
E 85/59 TBEV L A L P W K H E G A Q N W N N A E R 5/6 1/20 0/8 0/4 0/4 10/11 
NS1 154/88 TBEV E C P L E R R K T G V F T V A E F G 3/6 13/20 2/8 1/4 0/4 7/11 
NS2B 244/124 DENV2 G L L V I S G L F P V S I P I T A A 5/6 2/20 0/8 2/4 1/4 9/11 
NS3 340/142 TBEV P W L A W H V A A N V S S V T D R S 6/6 9/20 2/8 2/4 1/4 10/11 
NS4B 382/169 TBEV S E W T N V D I Q P A R S W G T Y V 1/6 9/20 0/8 2/4 0/4 5/11 
NS5 521/197 TBEV L N T L T N I K V Q L I R M M E G E 5/6 2/20 3/8 0/4 0/4 9/11 
NS5 521/198 TBEV N T L T N I K V Q L I R M M E G E G 5/6 2/20 1/8 0/4 0/4 9/11 
NS5 521/206 DENV3 G L N T F T N M E A Q L I R Q M E G 4/6 2/20 7/8 0/4 0/4 8/11 
NS5 531/223 TBEV P L D D R F G K A L Y F L N D M A K 4/6 6/20 1/8 0/4 0/4 8/11 
NS5 532/250 TBEV G K A L Y F L N D M A K T R K D I G 2/6 10/20 1/8 0/4 0/4 6/11 
NS5 552/277 TBEV W S I H A S G A W M T T E D M L D V 3/6 8/20 1/8 0/4 0/4 8/11 
Of these peptides, the peptide E-74/38 (aa 443-460/aa 162–179 of E) lies in the domain I and 
the peptide E-85/59 (aa 503-520/aa 222–239 of E) in the domain II of the E protein (Figure 
2). Amino acid residues in peptide E-85/59 fell into a region that has been identified in low 
pH-induced fusion with endosomal membrane (residues 221–240) [13,14]. Based on peptide 
sequence alignments, the minimal amino acid sequence for the peptide E-74/38 is 14 amino 
acids and it differed from the other tick-borne flaviviruses by a minimum of one C-terminal 
residue (Figure 3A). However, as shown in Figure 2C, peptide E-74/38 represents a region 
with two antiparallel beta-sheets, and thus most likely forms a conformational epitope. For 
the peptide E-85/59, the minimal sequence recognized is 16 amino acids and it shows very 
little or no homology to other flavivirus heterologous peptides (Figure 3B). Also, the 
reactivity towards the peptide E-85/59 represents most likely a response towards a 
conformational epitope formed by a protruding loop of domain II in TBEV E protein (Figure 
2D). Peptide E-56/7 was found to cross-react with DENV and WNV sera pools. This peptide 
is located in domain II of the E protein (Figure 2A) and represents a long stretch of two beta 
sheets. This peptide would be only partially accessible in the virion, and most likely the C- 
and N-terminal portions of this peptide (separately) are involved in formation of a 
conformational epitope with other regions in domain II (Figure 2A). 
Figure 2 Location of the identified peptide epitopes in E protein structure. Left-hand 
panels show the secondary structure (dimer) and right-hand panels show the solvent 
accessible surface (monomer) of E protein. A) TBEV E protein dimer as viewed from above 
(the virion) colored (domain I in red, domain II in yellow, and domain III in blue) according 
to Rey F et al. (Rey et al. [13]). B) Peptide E-56/7 (residues 51–58, in domain 2), highlighted 
in red. C) Peptide E-74/38 (residues 163–180, in domain 1), highlighted in red. D) Peptide E-
85/59 (residues 223–240, in domain 2), highlighted in red. E) Peptides E-56/7, E-74/38, and 
E-85/59, highlighted in red. 
Figure 3 Clustal 2.1 multiple sequence alignment of the synthesized heterologous 
peptides with a) TBEV E-74 b) TBEV E-85 c) TBEV NS5-521. The line separates peptides 
reactive with TBEV-seropositive sera (above) from the non-reactive ones. Identical amino 
acids in grey. Conserved amino acids marked with asterisks. 
The third identified linear epitope NS5-521/198 was in the C-terminal RNA-polymerase 
region of the NS5 protein (aa 3123-3140/aa 612–629) [6]. The minimal amino acid sequence 
for NS5-521/198 (Figure 3C) differs by a minimum of two amino acids from other tick-borne 
flaviviruses. The parent peptide 521 is identical to the corresponding peptide from Omsk 
hemorrhagic fever virus (OHFV, Figure 3C). However, the parent peptide yielded only 
borderline positive values in quantitation whereas more clearly positive values with less 
cross-reactivity were obtained with peptide NS5-521/198 containing two additional amino 
acids. Since a 3D structure is available for the NS5 of several flaviviruses, excluding TBEV, 
we used homology modeling to generate a model for TBEV NS5 structure. The peptide NS5-
521/198 (Figure 4C) is located in the palm domain of TBEV NS5 (Figure 4B, residues 499–
541 and 610–717). In addition, two of the other peptide epitopes (NS5-531/223 and NS5-
532/250, Figure 4D and E, respectively, excluded due to cross-reactivity) in NS5 lie in the 
palm domain. The third dominant, but rather cross-reactive, epitope in NS5 (peptide NS5-
552/277) is located in the thumb domain in the TBEV NS5 structure model (Figure 4F). 
Figure 4 Three-dimensional model of TBEV NS5 structure with the identified peptide 
epitopes. A) Ribbon diagram of TBEV NS5 model. B) Palm domain of TBEV NS5 model 
(according to analogy to WNV NS5 (Malet et al., [28]), highlighted in yellow. C) Peptide 
NS5-521/198 (residues 612–629), highlighted in red. D) Peptide NS5-531/223 (residues 670–
687), highlighted in red. E) Peptide NS5-532/250 (residues 676–683), highlighted in red. F) 
Peptide NS5-552/277 (residues 796–813), highlighted in red. G) Peptides NS5-521/198, 
NS5-531/223, and NS5-532/250, highlighted in red. H) Peptides NS5-521/198, NS5-531/223, 
NS5-532/250, and NS5-552/277, highlighted in red. 
Linear epitopes in natural versus vaccine-induced TBEV immunity 
Finally, to compare the B-cell epitope responses induced by vaccination and infection, we 
probed the new membrane with eight serum samples of persons immunized and showing 
neutralizing antibody responses against TBEV. None of the eight sera recognized the peptide 
E-85/59, suggesting that fixation used in virus inactivation might alter the conformation of 
this potentially conformational epitope (Figure 2D). 
One out of eight sera recognized the peptide E-74/38 that also likely represents a 
conformational epitope (Figure 2C, Table 4). The results summarizing the new membrane 
using individual serum samples are given in Table 4. Curiously, quite a strong cross-
reactivity with a peptide from DENV3 NS5 (corresponding to the peptide NS5-521/206) was 
seen with the serum of several TBEV-immunized individuals (Table 4). Only 1/8 TBEV-
immunized serum samples recognized the NS5-521/198 peptide (Table 4). Many of the sera 
from TBEV-immunized individuals reacted with peptide epitopes that were not recognized 
by sera of TBEV-infected and TBEV-seronegative individuals (Table 5). These peptides, 
mostly located in the E protein, could be rendered more antigenic due to fixation required for 
virus inactivation. 
Table 5 Peptides specific for TBEV-immunized individuals 
Protein Index Peptide sequence 
prM 24 Q V R V E N G T C V I L A T D M G S 
prM 29 I D Q G E E P V D V D C F C R N V D 
E 61 T L A E E H Q G G T V C K R D Q S D 
E 65 C G L F G K G S I V A C V K A A C E 
E 72 T G D Y V A A N E T H S G R K T A S 
E 88 E F G A P H A V K M D V Y N L G D Q 
E 95 S G H V T C E V G L E K L K M K G L 
E 96 E V G L E K L K M K G L T Y T M C D 
E 101 S G H D T V V M E V T F S G T K P C 
E 121 L G G A F N S I F G G V G F L P K L 
E 122 S I F G G V G F L P K L L L G V A L 
Discussion 
Currently, TBE diagnostics is based on assays measuring IgM and IgG antibody responses to 
purified viral particles or consisting of structural proteins, or in some cases recombinant 
virus-like particles [15,16]. TBEV E-protein is highly cross-reactive among other members of 
the genus Flavivirus and thus the identification of TBEV-specific antigenic regions would be 
beneficial. The cross-reactivity between flaviviruses is mainly due to conformational 
epitopes, and therefore linear epitopes presented as peptides could represent a useful 
alternative for traditionally used purified virus or recombinant protein diagnostic antigens. 
Ideally, such antigens could enable differential diagnostics between flaviviruses, and perhaps 
also between natural TBEV infection and vaccine responses. On the other hand, the potential 
of the nonstructural proteins as antigens is currently not fully explored. Our study provides 
one holistic approach for screening antigenic areas with diagnostic potential. For mosquito-
borne flaviviruses, Wong et al. have developed an NS5-based serological test for 
differentiating natural WNV-infection from other flavivirus infections (specifically Saint 
Louis encephalitis and dengue virus) [17]. 
In this study, we describe the mapping of linear B-cell IgG epitopes in the TBEV proteome. 
Initial mapping using TBEV-seronegative and acute TBEV-seropositive serum pools 
revealed several regions containing linear epitopes throughout the TBEV proteome. Further 
analysis of the epitope regions using individual serum samples revealed that most of the 
epitopes were not recognized by all of the positive samples. After data analysis, we selected 
11 peptides in total from E, NS1, NS2B, NS3, NS4B and NS5 proteins for more thorough 
characterization. In addition, we addressed the cross-reactivity of TBEV seropositive sera 
against the corresponding regions from other flaviviruses. Eventually, we identified three 
TBEV-specific epitope regions that reacted with the majority of TBEV seropositive sera. 
Two of the identified peptides are in the E protein and one in the NS5 protein region. Of 
these, peptide E-85/59 showed the highest specificity and potential in serological 
differentiation between natural and vaccine-derived immunity. Holzmann et al. used a similar 
type of approach to study linear epitopes in TBEV E protein utilizing mouse monoclonal 
antibodies. Their results demonstrated that only few of the MAbs reacted with synthetic 
peptides from TBEV E protein. Curiously, these MAbs bound only TBEV E protein only if 
directly coated on microtitre plate or otherwise denatured [18]. However, in our study we 
were able to demonstrate several linear epitopes throughout TBEV E protein. Peptide E-
85/59, the region identified by Holzmann et al. as an epitope for TBEV MAb, was recognized 
only by sera of infected individuals and not by sera of vaccinated individuals. 
The space-filling model of the E protein (Figure 2) demonstrates that the identified peptides 
lie on the surface of the folded protein. Furthermore, both E-74/38 and E-85/59 that are 
located in domains I and II, respectively, actually form or are parts of a conformational 
epitope (Figure 2C and D). Neither of these peptides was reactive with sera of TBEV-
immunized individuals, thus suggesting that the conformational epitopes at these regions are 
affected by the fixation used for virus inactivation. Furthermore, we observed that the sera of 
TBEV-immunized individuals recognized several epitopes in the E protein that were less 
reactive with sera of naturally infected TBEV-seropositive individuals. This probably 
highlights the fact that the natural B-cell response towards TBEV, and perhaps towards 
flaviviruses in general, is based on conformational epitopes. Although vaccination using 
formalin-fixed inactivated virions is effective, stronger responses would obviously be 
obtained with replication in cells or with native proteins. 
We generated a homology model for TBEV NS5 to visualize the epitopes found in this 
region. The peptides NS5-521/198, NS5-531/223 and NS5-532/250 identified in this study, 
are located in the palm domain in the TBEV NS5 structure model. Of these peptides, NS5-
521/198 is identical to the respective region in Omsk hemorrhagic virus NS5. The parent 
peptide reacted (positive with 6/6 of TBE patient and 3/20 of seronegative samples) rather 
similarly with the OMSKV peptide (positive with 4/6 of TBE patient and 3/20 of 
seronegative samples). Thus it seems evident that OMSKV-seropositive serum would also 
recognize this peptide epitope. However, since a couple of epitopes are located in the palm 
domain of TBEV NS5, one could envision using this region as recombinant antigen for 
flavivirus diagnostics. 
Throughout our study we used densitometry to quantify the signal intensities of the individual 
peptides on the SPOT array. However, since the detection of SPOT binding is based on an 
enzymatic reaction, many factors contribute to the signal intensity (incubation and exposure 
times, membrane regeneration, antibody dilutions, ECL reagents, etc.). Quantification can 
therefore be done only inside the array and not between individual serum samples. Due to 
this, we evaluated each membrane individually, and considered peptides positive if the 
intensity was above a certain assay-specific threshold value. However, this method brings out 
a challenge in selecting the true-positive peptides, and vice versa, it is likely to miss some 
potential spots under the arbitrary threshold. As exemplified by a slight discrepancy in the 
results obtained with DENV2 (3/6 were positive) and DENV3 (4/6 were positive) peptides 
having identical sequences. This discrepancy is directly explained by the selected threshold 
values and the factors described above. Additionally, the regeneration steps required for re-
use of the SPOT peptide array membranes are not ideal for high throughput screening. Thus 
we will, in the near future, synthesize some of the promising peptides found in this study in 
soluble form, and use them as antigens in an enzyme-linked immunosorbent assay (ELISA) 
format. ELISA will allow us to further test these peptides with larger serum panels and at 
different dilutions. 
Conclusions 
In conclusion, we have for the first time characterized the linear human B-cell epitopes of 
TBEV using TBE-patient and cross-reacting flavivirus sera. The TBE patients’ sera detect 
peptide targets particularly on the surface of E and NS5 proteins, and two of these peptides 
seem promising in distinguishing between TBEV and other flavivirus infections or TBEV 
vaccine derived immunity. 
Methods 
Computer analysis 
The putative hydrophobic and hydrophilic areas of the coding region of TBEV European 
subtype strain Kumlinge A52 genome (GenBank accession number GU183380) [19,20] were 
predicted by the Kyte and Doolittle method using MacVector software. 
Peptide synthesis 
The whole coding region of TBEV genome strain Kumlinge A52 was synthesized onto an 
amino-PEG membrane in 567 18-amino acid peptides with six amino acid transition [21]. 
Based on the initial screening with 567 peptides covering the proteome of TBEV, we selected 
11 peptides (Table 1) for further evaluation. Six amino acids were added to both N- and C-
terminus of these peptides, which were then synthesized as 18-amino acid peptides with one 
amino acid transition. Heterologous peptides corresponding to the “parent” peptide (Table 2) 
were synthesized from other tick- and mosquito-borne flaviviruses. Peptide synthesis was 
conducted with a MultiPep platform (Intavis Ag) utilizing Fmoc chemistry as described 
earlier [22]. 
SPOT method 
The membrane containing the complete proteome of TBEV was initially probed with a pool 
of sera from TBEV seronegative patients (N = 5), next with a pool of sera from TBEV-
immunized individuals (N = 8), then with a pool of sera from TBE patients (N = 5), and 
finally with individual serum samples collected from acute-phase TBE patients (N = 5). The 
membrane with peptides selected based on initial screening (11 “parent” peptides, Table 1) 
was probed individually with six paired serum samples from acute-phase TBE patients and 
with sera from 8 TBEV-immunized individuals. The probing and detection of SPOT 
membranes was done as previously described [23]. Briefly, the sera were used at 1:500 
dilution (in pools the total serum dilution was 1:500). The binding of antibodies was detected 
by HRP-labeled anti-human IgG (DakoCytomation) at 1:1000 dilution and the results were 
visualized utilizing enhanced chemiluminescence as recorded on X-ray film (Fuji RX 
medical). 
Serum samples 
Five acute-phase TBEV-seropositive and five TBEV-seronegative patient sera were selected 
from serum samples sent to and tested at the Helsinki University Central Hospital Laboratory 
(HUSLAB), Department of Virology and Immunology. TBEV-seropositive sera were IgM 
and IgG positive in routinely used serological tests. 
The panel of 6 paired serum samples of acute TBE patients and eight serum samples of 
TBEV-immunized people were collected in Sweden. These sera were characterized by 
neutralization inhibition at The Public Health Agency of Sweden, Solna, Sweden. The 
samples of immunized individuals were taken before and after the third vaccine dose of the 
TBEV vaccination programme. Both sample sets were found TBEV IgM and IgG positive in 
routinely used serological tests at HUSLAB, Department of Virology and Immunology. 
Four pools of WNV patient sera were obtained through ENIVD network (European Network 
on Improted Viral Diseases, www.envid.de). A total of four DENV IgM and IgG positive 
patient serum samples (each representing primary infections with a different serotype, 
DENV-1-4), as determined by RT-PCR [24] were selected from patient samples sent to and 
tested at HUSLAB, Department of Virology and Immunology. 
Densitometric analysis of peptide intesinty 
The results of SPOT analysis recorded on X-ray film were scanned using flatbed scanner 
(CanoScan LIDE 70) as TIFF files. The SPOT intensities were quantitated using Chemidoc 
XRS (Bio-Rad). Specific threshold values were assigned for each array individually. 
Protein structures and homology modelling 
To visualize the peptide epitopes discovered, we generated a three-dimensional model for 
TBEV A52 Kumlinge NS5 protein structure using Swiss-Model in Automatic Modelling 
Mode [25]. Swiss-Model chose WNV NS5 protein (pdb code 2HFZ) [26-29] with a sequence 
identity of 62.1% to TBEV NS5 as the template for model building. The generated model had 
a QMEAN6 score of 0.652 with a Z-Score of −1.227 [30]. Based on the QMEAN6 score, we 
estimated the model to be accurate enough for visualization of the peptide epitopes. 
The TBEV E protein structure (1SVB) was obtained from the protein data bank. The domains 
of E protein were colored as previously described [13] using YASARA [31]. The epitope 
peptides were highlighted in both TBEV NS5 model and in TBEV E protein structure using 
YASARA. 
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